EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib By Ogkologos - May 22, 2026 100 0 Facebook Twitter Google+ Pinterest WhatsApp Palbociclib Viatris is a generic of Ibrance which has been authorised in the EU since 2016 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... November 18, 2025 During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... April 14, 2020 ESMO Congress 2021, 16-21 September September 2, 2021 Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance December 4, 2025 Load more HOT NEWS Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in... Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma Group of Breast Cancer Survivors is Finding New Strength from Fitness...
